Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 3001 - 3100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 3001 | 26630661 |
US |
32 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3002 | 26630663 |
US |
2 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3003 | 26630666 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3004 | 26630688 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3005 | 26630726 |
US |
14 | 1 |
Rash erythematous, Sleep disorder, Dry skin, Pruritus, Dermatitis atopic, Product dose omission issue, Skin weeping, Skin exfoliation, |
||||
DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3006 | 26630730 |
US |
56 | |
Psoriatic arthropathy, Peripheral swelling, Joint swelling, Arthralgia, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 3007 | 26630732 |
US |
2 | |
Pruritus, Rhinorrhoea, Pain, Chills, Pyrexia, Dermatitis atopic, Dry skin, Sleep disorder, Scratch, |
||||
DUPILUMAB, DUPILUMAB, AMLODIPINE BESYLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, AZELASTINE HYDROCHLORIDE, AZELASTINE, DAPAGLIFLOZIN, FISH OIL, FINERENONE, LISINOPRIL, MOMETASONE FUROATE, MOMETASONE, PENTOXIFYLLINE, PIOGLITAZONE, PANTOPRAZOLE SODIUM, REPAGLINIDE, REPAGLINIDE, LINAGLIPTIN, LINAGLIPTIN, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ICOSAPENT ETHYL, CEFADROXIL, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 3008 | 26630790 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3009 | 26630806 |
US |
2 | |
Sleep disorder due to a general medical condition, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 3010 | 26630811 |
US |
2 | |
Dermatitis atopic, Skin haemorrhage, |
||||
DUPILUMAB, |
||||
| 3011 | 26630818 |
US |
42 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3012 | 26630832 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3013 | 26630848 |
US |
40 | 1 |
Dermatitis atopic, Skin fissures, Rash, |
||||
DUPILUMAB, |
||||
| 3014 | 26630859 |
US |
5 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3015 | 26630862 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, BENZONATATE, CHLORTHALIDONE, FINASTERIDE, VIBEGRON, LABETALOL HYDROCHLORIDE, LABETALOL, INSULIN GLARGINE, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST, NIFEDIPINE, INSULIN ASPART, ORAL SEMAGLUTIDE, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE INHALATION SPRAY, VITAMIN C, |
||||
| 3016 | 26630868 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3017 | 26630919 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, FLUOCINONIDE, FLUOCINONIDE TOPICAL SOLUTION USP, 0.05%, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, |
||||
| 3018 | 26630924 |
US |
1 | |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, |
||||
| 3019 | 26630926 |
US |
2 | |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 3020 | 26630937 |
US |
72 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3021 | 26630938 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3022 | 26630949 |
US |
19 | 1 |
Sleep disorder due to a general medical condition, Discomfort, Dermatitis atopic, Rash, Product dose omission issue, Therapeutic response decreased, Drug ineffective, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CETIRIZINE HCL, CETIRIZINE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, PREDNISONE, CETIRIZINE HYDROCHLORIDE, PREDNISONE, |
||||
| 3023 | 26631132 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3024 | 26631140 |
US |
59 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3025 | 26631141 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3026 | 26631143 |
US |
9 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3027 | 26631144 |
US |
1 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3028 | 26631146 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3029 | 26631148 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3030 | 26631218 |
US |
90 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3031 | 26631226 |
US |
53 | 1 |
Fungal infection, Dermatitis atopic, Pruritus, Skin swelling, Skin exfoliation, Eczema, Varicella, Rash, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, RISANKIZUMAB-RZAA, |
||||
| 3032 | 26631238 |
US |
36 | 2 |
Lacrimation increased, Ocular hyperaemia, Erythema of eyelid, Eye pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3033 | 26631249 |
US |
76 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3034 | 26631250 |
US |
59 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3035 | 26631258 |
US |
74 | 1 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 3036 | 26631288 |
US |
32 | 1 |
Dermatitis atopic, Pruritus, Erythema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3037 | 26631294 |
US |
30 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3038 | 26631303 |
US |
58 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 3039 | 26631316 |
US |
58 | 1 |
Dermatitis atopic, Rebound atopic dermatitis, Dry skin, Skin fissures, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3040 | 26631457 |
US |
35 | 2 |
Dermatitis atopic, Injection site haemorrhage, Injection site swelling, |
||||
DUPILUMAB, |
||||
| 3041 | 26631461 |
US |
26 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 3042 | 26632848 |
CA |
||
Abdominal abscess, Dermatitis atopic, Gait disturbance, Discomfort, Off label use, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 3043 | 26633823 |
US |
10 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, MONTELUKAST SODIUM, MONTELUKAST, LEVOCETIRIZINE DIHYDROCHLORIDE, FLUTICASONE PROPIONATE, |
||||
| 3044 | 26622681 |
US |
44 | 2 |
Vision blurred, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 3045 | 26622748 |
US |
72 | 2 |
Pruritus, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 3046 | 26623131 |
US |
66 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3047 | 26623133 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3048 | 26623162 |
US |
37 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 3049 | 26623164 |
US |
56 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3050 | 26623169 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3051 | 26623179 |
US |
74 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3052 | 26623181 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3053 | 26623183 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3054 | 26623187 |
US |
21 | 1 |
Dermatitis atopic, Eczema, Injection site swelling, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3055 | 26623189 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3056 | 26623198 |
US |
64 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3057 | 26623202 |
US |
42 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3058 | 26623224 |
US |
31 | 2 |
Dermatitis allergic, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3059 | 26623225 |
US |
58 | 2 |
Scab, Infection, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3060 | 26623443 |
US |
17 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3061 | 26623444 |
US |
67 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3062 | 26623460 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3063 | 26623466 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, AMOXICILLIN, |
||||
| 3064 | 26623467 |
US |
1 | |
Injection site bruising, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3065 | 26623473 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3066 | 26623549 |
US |
39 | 1 |
Pruritus, Scratch, Dermatitis atopic, Dermatitis, Dry skin, |
||||
DUPILUMAB, |
||||
| 3067 | 26623579 |
US |
31 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3068 | 26623610 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3069 | 26623638 |
US |
61 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 3070 | 26623639 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3071 | 26623682 |
US |
84 | 1 |
Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3072 | 26623684 |
US |
2 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3073 | 26623709 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3074 | 26623737 |
US |
85 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3075 | 26623745 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3076 | 26623919 |
US |
69 | 1 |
Dermatitis atopic, Product dose omission issue, Knee arthroplasty, |
||||
DUPILUMAB, |
||||
| 3077 | 26623947 |
US |
57 | |
Skin weeping, Dry skin, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 3078 | 26624039 |
US |
2 | |
Dermatitis atopic, Drug effect less than expected, Off label use, |
||||
DUPILUMAB, |
||||
| 3079 | 26624133 |
US |
2 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3080 | 26624184 |
US |
2 | |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3081 | 26624348 |
US |
||
Dermatitis atopic, Weight increased, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 3082 | 26624388 |
US |
34 | 2 |
Dermatitis atopic, Intentional dose omission, Seasonal allergy, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 3083 | 26624405 |
US |
34 | 1 |
Dermatitis atopic, Eye swelling, Rash, Dry skin, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3084 | 26624431 |
US |
3 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3085 | 26624471 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, CLONAZEPAM, ROSUVASTATIN, FAMOTIDINE, |
||||
| 3086 | 26624482 |
US |
2 | |
Scratch, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3087 | 26624512 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3088 | 26624516 |
US |
27 | 1 |
Dermatitis atopic, Pruritus, Dry skin, Eczema, |
||||
DUPILUMAB, WHITE PETROLATUM, BABY PETROLEUM JELLY, PETROLATUM, PETROLEUM JELLY, WHITE PETROLATUM JELLY, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3089 | 26624558 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3090 | 26624571 |
US |
61 | 2 |
Dermatitis atopic, Scar, Product dose omission issue, Therapeutic response decreased, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 3091 | 26624598 |
US |
1 | |
Skin exfoliation, Skin erosion, Erythema, Dermatitis atopic, Scar, Product dose omission issue, |
||||
DUPILUMAB, ALBUTEROL SULFATE, MELOXICAM, CARBOXYMETHYLCELLULOSE SODIUM, THIAMINE HYDROCHLORIDE, VITAMIN C, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 3092 | 26624603 |
US |
14 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 3093 | 26624609 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3094 | 26624659 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3095 | 26624904 |
US |
75 | 2 |
Dermatitis atopic, Asthma, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 3096 | 26624957 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 3097 | 26625874 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3098 | 26627687 |
CA |
77 | 1 |
Hospitalisation, Acne, Haematochezia, Polyp, Dermatitis atopic, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 3099 | 26627692 |
US |
1 | |
Sleep disorder due to a general medical condition, Dermatitis atopic, Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, MELATONIN, |
||||
| 3100 | 26616611 |
US |
||
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30